Scholarlink

Purpose <p>Polycystic liver disease is the most prevalent extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). Non-obstructive asymptomatic common bile duct (CBD) dilatation has been observed anecdotally on CT scans, but CT is not optimal for biliary visualization. Here, we measured CBD diameter on T2-weighted MRI in ADPKD subjects to determine if CBD dilatation is associated with ADPKD.</p> Methods <p>CBD diameter was measured retrospectively on ADPKD subjects (<i>n</i> = 254) and on age- and sex-matched controls without ADPKD (<i>n</i> = 254) who underwent abdominal MRI. CBD diameter in these groups was compared and correlated with clinical, laboratory and magnetic resonance imaging (MRI) features, including organ volumes and cyst burden.</p> Results <p>CBD median diameter [interquartile range, IQR, 25%, 75%] was 22% larger in ADPKD compared to controls (5.6 [4.7, 6.9] mm vs. 4.6 [3.9, 5.4] mm, <i>p</i> &lt; 0.001). CBD diameter measurements had excellent inter-observer agreement (Intraclass correlation coefficient = 0.92). Thirteen (5.1%) ADPKD subjects had a CBD diameter <i>≥</i> 10&#xa0;mm compared to 1 (0.4%) control subject (<i>p</i> &lt; 0.001). Multivariable analysis found the presence of <i>PKD1</i> or <i>PKD2</i> mutation <b>(</b>beta = 1.5, <i>P</i> &lt; 0.001) and age (beta = 0.04, <i>p</i> &lt; 0.001) to be associated with increased CBD diameter and serum albumin associated with decreased CBD diameter (beta=-0.39, <i>p</i> &lt; 0.001).</p> Conclusion <p>ADPKD subjects had 22% larger CBD diameters than in non-ADPKD controls and were more likely to have CBD dilatation <i>≥</i> 10&#xa0;mm without CBD obstruction. Awareness of this association of non-obstructive CBD dilatation with ADPKD may limit unnecessary diagnostic testing.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Common bile duct dilatation on MRI in autosomal dominant polycystic kidney disease

  • 期刊论文

  • 发表日期：

    2025年7月17日

查看全文
  • Usama Sattar,
  • Chenglin Zhu,
  • Xiaorui Yin,
  • Xianfu Luo,
  • Vahid Bazojoo,
  • Albert S. Prince,
  • Hanna Rennert,
  • Danielle Brandman,
  • Emily Schonfeld,
  • Jon D. Blumenfeld,
  • Martin R. Prince

摘要

Purpose

Polycystic liver disease is the most prevalent extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). Non-obstructive asymptomatic common bile duct (CBD) dilatation has been observed anecdotally on CT scans, but CT is not optimal for biliary visualization. Here, we measured CBD diameter on T2-weighted MRI in ADPKD subjects to determine if CBD dilatation is associated with ADPKD.

Methods

CBD diameter was measured retrospectively on ADPKD subjects (n = 254) and on age- and sex-matched controls without ADPKD (n = 254) who underwent abdominal MRI. CBD diameter in these groups was compared and correlated with clinical, laboratory and magnetic resonance imaging (MRI) features, including organ volumes and cyst burden.

Results

CBD median diameter [interquartile range, IQR, 25%, 75%] was 22% larger in ADPKD compared to controls (5.6 [4.7, 6.9] mm vs. 4.6 [3.9, 5.4] mm, p < 0.001). CBD diameter measurements had excellent inter-observer agreement (Intraclass correlation coefficient = 0.92). Thirteen (5.1%) ADPKD subjects had a CBD diameter ≥ 10 mm compared to 1 (0.4%) control subject (p < 0.001). Multivariable analysis found the presence of PKD1 or PKD2 mutation (beta = 1.5, P < 0.001) and age (beta = 0.04, p < 0.001) to be associated with increased CBD diameter and serum albumin associated with decreased CBD diameter (beta=-0.39, p < 0.001).

Conclusion

ADPKD subjects had 22% larger CBD diameters than in non-ADPKD controls and were more likely to have CBD dilatation ≥ 10 mm without CBD obstruction. Awareness of this association of non-obstructive CBD dilatation with ADPKD may limit unnecessary diagnostic testing.